ITA2990
ITA2990
- Catalog: ITA2990
- Gene/Protein: TARBP2
- Product Description: Immunotag™ TRBP Antibody
385.0000
Price in reward points: 385
| Antibody Specification | |
| Datasheet |
|
| Target Protein | TRBP |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,IHC |
| Recommended Dilution | WB 1:500-1:2000, IHC 1:50-1:200 |
| Concentration | 1 mg/ml |
| Reactive Species | Human,Mouse,Rat |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide derived from human TRBP. |
| Specificity | TRBP antibody detects endogenous levels of TRBP. |
| Purification | The antiserum was purified by peptide affinity chromatography. |
| Form | Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt |
| Gene Name | TARBP2 |
| Accession No. | Q15633 |
| Alternate Names | LOQS; Prbp; RISC loading complex subunit TARBP2; RISC-loading complex subunit tarbp2; TAR (HIV 1) RNA binding protein 2; TAR (HIV) RNA binding protein 2; TAR (HIV) RNA-binding protein TRBP1; TAR RNA Binding Protein 2; TAR RNA-binding protein 2; tarbp2; TARBP2 RISC loading complex RNA binding subunit; Trans-activation-responsive RNA-binding protein; TRBP; TRBP1; TRBP2; TRBP2_HUMAN; |
| Description | Required for formation of the RNA induced silencing complex (RISC). Component of the RISC loading complex (RLC), also known as the micro-RNA (miRNA) loading complex (miRLC), which is composed of DICER1, AGO2 and TARBP2. Within the RLC/miRLC, DICER1 and TARBP2 are required to process precursor miRNAs (pre-miRNAs) to mature miRNAs and then load them onto AGO2. AGO2 bound to the mature miRNA constitutes the minimal RISC and may subsequently dissociate from DICER1 and TARBP2. May also play a role in the production of short interfering RNAs (siRNAs) from double-stranded RNA (dsRNA) by DICER1. Binds to the HIV-1 TAR RNA which is located in the long terminal repeat (LTR) of HIV-1, and stimulates translation of TAR-containing RNAs. This is achieved in part at least by binding to and inhibiting EIF2AK2/PKR, thereby reducing phosphorylation and inhibition of EIF2S1/eIF-2-alpha. May also promote translation of TAR-containing RNAs independently of EIF2AK2/PKR. |
| Cell Pathway/ Category | Primary Polyclonal Antibody |
| Protein MW | 43-46 kDa |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |
| Material Safety Data Sheet | |
| English_US |
|
| Danish |
|
| Dutch |
|
| English_UK |
|
| French |
|
| German |
|
| Spanish |
|
| Norwegian |
|
| Portuguese |
|
| Finnish |
|
| Swedish |
|
| Polish |
|